Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 3145 (LINC03145)
- Target
- LINC03145
- Molecular classification
- Long noncoding RNA (lncRNA), Long intergenic noncoding RNA (lincRNA), Competing endogenous RNA (ceRNA), Other
01
Overview
Long intergenic non-protein coding RNA 3145 (LINC03145), also known as CRART16 or cetuximab resistance-associated RNA transcript 16, is a long intergenic noncoding RNA shown to be upregulated in cetuximab-resistant colorectal cancer cells[2][4][6]. It acts as a competing endogenous RNA by sponging miR-371a-5p, leading to increased ERBB3 expression and downstream activation of the MAPK signaling pathway, contributing to both drug resistance and the acquisition of cancer stemness properties. CRART16 serves as a biomarker for cetuximab resistance and is considered a potential therapeutic target for overcoming resistance in colorectal cancer[2][4][6].
- Other names
- LINC03145CRART16cetuximab resistance-associated RNA transcript 16ENST00000564193.1
02
Mechanism of action
Acts as a competing endogenous RNA (ceRNA) by sponging miR-371a-5p, leading to increased ERBB3 expression and activation of downstream pathways, resulting in drug resistance
03
Biological functions
Regulation of gene expression (via miRNA sponge function)Promotion of cell stemness propertiesMediation of drug resistance (specifically cetuximab resistance)Participation in MAPK signaling pathwayOther
04
Disease associations
CancerChemoresistance (colorectal cancer, cetuximab resistance)Other
05
Safety considerations
None specifically documented; therapeutic targeting may present challenges typical of lncRNA-based interventions (specificity, delivery)
06
Interacting drugs
Cetuximab
07
Biomarkers
Upregulation as biomarker for cetuximab resistance in colorectal cancer
Beyond the preview
Go deeper on Long intergenic non-protein coding RNA 3145 (LINC03145).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Long intergenic non-protein coding RNA 3145 (LINC03145).